Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 SoligenixForward Pharma A/SCumberland PharmaceuticalsRegulus TherapeuticsLixte Biotechnology
SymbolNASDAQ:SNGXNASDAQ:FWPNASDAQ:CPIXNASDAQ:RGLSNASDAQ:LIXT
Price Information
Current Price$1.35$7.16$2.88$1.21$2.54
52 Week RangeBuyN/ABuyHoldN/A
MarketRank™
Overall Score1.40.70.90.90.0
Analysis Score3.30.00.01.20.0
Community Score2.92.82.22.90.0
Dividend Score0.00.00.00.00.0
Ownership Score0.00.00.80.00.0
Earnings & Valuation Score0.60.61.30.60.0
Analyst Ratings
Consensus RecommendationBuyN/ABuyHoldN/A
Consensus Price Target$3.44N/AN/A$1.25N/A
% Upside from Price Target154.63% upsideN/AN/A3.31% upsideN/A
Trade Information
Market Cap$54.03 million$48.62 million$42.97 million$87.73 million$34.39 million
Beta1.421.850.322.41-1.15
Average Volume3,674,33361,63061,4762,939,743903,836
Sales & Book Value
Annual Revenue$4.60 millionN/A$47.53 million$6.83 millionN/A
Price / Sales11.75N/A0.9012.84N/A
CashflowN/AN/A$0.46 per shareN/AN/A
Price / CashN/AN/A6.25N/AN/A
Book Value$0.07 per share$11.42 per share$3.36 per share$0.95 per shareN/A
Price / Book19.29N/A0.861.27N/A
Profitability
Net Income$-9,360,000.00$-4,220,000.00$-3,540,000.00$-18,590,000.00N/A
EPS($0.48)N/A$0.23($1.08)N/A
Trailing P/E RatioN/A0.00N/AN/A0.00
Forward P/E RatioN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net Margins-567.04%N/A-8.36%N/AN/A
Return on Equity (ROE)-328.25%N/A3.86%-150.66%N/A
Return on Assets (ROA)-140.08%N/A1.92%-57.52%N/A
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity Ratio0.02%N/A0.31%N/AN/A
Current Ratio2.30%118.57%2.04%1.35%N/A
Quick Ratio2.30%N/A1.62%1.35%N/A
Ownership Information
Institutional Ownership Percentage9.39%12.88%26.15%19.96%N/A
Insider Ownership Percentage3.09%N/A39.72%18.24%N/A
Miscellaneous
Employees15590241
Shares Outstanding40.02 million6.79 million14.92 million72.51 million13.54 million
Next Earnings Date5/21/2021 (Estimated)4/23/2021 (Estimated)5/19/2021 (Estimated)5/13/2021 (Estimated)N/A
OptionableNot OptionableNot OptionableOptionableOptionableNot Optionable
SourceHeadline
Short Interest in Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Grows By 151.5%Short Interest in Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) Grows By 151.5%
americanbankingnews.com - April 14 at 1:00 PM
Highlights From Day 1 Of Benzingas Biotech Small Cap ConferenceHighlights From Day 1 Of Benzinga's Biotech Small Cap Conference
feeds.benzinga.com - March 25 at 2:48 PM
Lixte Biotechnology to Present Its Novel Product Candidate for Targeted Cancer Therapy at the Benzinga Biotech Small Cap Conference on March 24Lixte Biotechnology to Present Its Novel Product Candidate for Targeted Cancer Therapy at the Benzinga Biotech Small Cap Conference on March 24
finance.yahoo.com - March 17 at 12:48 PM
Lixte Jumps on Direct OfferingLixte Jumps on Direct Offering
baystreet.ca - March 15 at 1:34 PM
Lixte Biotechnology to Showcase Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual 33rd ...Lixte Biotechnology to Showcase Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual 33rd ...
apnews.com - March 3 at 12:47 PM
Lixte Biotechnology to Showcase Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual 33rd Annual ROTH Capital ConferenceLixte Biotechnology to Showcase Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual 33rd Annual ROTH Capital Conference
finance.yahoo.com - March 3 at 12:47 PM
Guardion Health Sciences Inc Registered Shs Stock , GHSIGuardion Health Sciences Inc Registered Shs Stock , GHSI
markets.businessinsider.com - March 3 at 2:46 AM
WallachBeth Capital Announces Completion of $4.19 Million Registered Direct Offering for Lixte Biotechnology Holdings, Inc.WallachBeth Capital Announces Completion of $4.19 Million Registered Direct Offering for Lixte Biotechnology Holdings, Inc.
prnewswire.com - March 2 at 4:12 PM
Lixte Biotechnology Announces the Closing of $4.19 Million Registered Direct OfferingLixte Biotechnology Announces the Closing of $4.19 Million Registered Direct Offering
finance.yahoo.com - March 2 at 11:44 AM
Lixte Biotechnology Announces $4.19 Million Registered Direct OfferingLixte Biotechnology Announces $4.19 Million Registered Direct Offering
finance.yahoo.com - March 1 at 12:43 PM
Lixte Biotech shares are trading higher. Not seeing any company-specific news to justify the price action.Lixte Biotech shares are trading higher. Not seeing any company-specific news to justify the price action.
benzinga.com - February 28 at 2:57 PM
Are These The Top Biotech Stocks To Buy In March? 4 Names To ConsiderAre These The Top Biotech Stocks To Buy In March? 4 Names To Consider
nasdaq.com - February 26 at 7:57 PM
Stock Alert: Lixte Biotechnology Up 55%Stock Alert: Lixte Biotechnology Up 55%
markets.businessinsider.com - February 26 at 2:56 PM
LIXT Stock: 8 Things to Know About Lixte Biotechnology As Shares Blast OffLIXT Stock: 8 Things to Know About Lixte Biotechnology As Shares Blast Off
feedproxy.google.com - February 26 at 12:18 PM
LIXT Stock: Here’s Why Lixte Biotechnology is SoaringLIXT Stock: Here’s Why Lixte Biotechnology is Soaring
cnafinance.com - February 26 at 9:56 AM
We Think Lixte Biotechnology Holdings (NASDAQ:LIXT) Needs To Drive Business Growth CarefullyWe Think Lixte Biotechnology Holdings (NASDAQ:LIXT) Needs To Drive Business Growth Carefully
finance.yahoo.com - February 25 at 12:47 PM
Lixte Biotechnology to Present Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual H.C. Wainwright Global Life Sciences ConferenceLixte Biotechnology to Present Its Anti-Cancer Therapy Enhancer LB-100 at the Virtual H.C. Wainwright Global Life Sciences Conference
finance.yahoo.com - February 24 at 9:49 AM
Lixte Biotechs lead candidate to be tested in small cell lung cancer patientsLixte Biotech's lead candidate to be tested in small cell lung cancer patients
seekingalpha.com - January 27 at 6:37 PM
Lixte Biotechnology and City of Hope to Initiate Phase 1b Clinical Trial of Lixte’s Lead ...Lixte Biotechnology and City of Hope to Initiate Phase 1b Clinical Trial of Lixte’s Lead ...
apnews.com - January 20 at 4:58 AM
Stock Alert: Lixte Biotechnology Adds 15% Following Deal With City Of HopeStock Alert: Lixte Biotechnology Adds 15% Following Deal With City Of Hope
nasdaq.com - January 19 at 6:56 PM
Lixte Biotechnology Holdings IncLixte Biotechnology Holdings Inc
bloomberg.com - December 23 at 8:48 PM
Lixte Biotechnology’s PP2A Inhibitor, LB-100, Enhances the Effectiveness of PD1 Immune Blockade in Mouse Models of Glioblastoma Brain TumorsLixte Biotechnology’s PP2A Inhibitor, LB-100, Enhances the Effectiveness of PD1 Immune Blockade in Mouse Models of Glioblastoma Brain Tumors
finance.yahoo.com - December 23 at 10:48 AM
Lixte Biotechnology Holdings, Inc. Announces The Appointment Of Internationally Recognized Clinical Cancer Investigator, James S. Miser MD, As Chief Medical OfficerLixte Biotechnology Holdings, Inc. Announces The Appointment Of Internationally Recognized Clinical Cancer Investigator, James S. Miser MD, As Chief Medical Officer
finance.yahoo.com - December 23 at 10:48 AM
The Foundation for Angelman Syndrome Therapeutics (FAST) and Lixte Biotechnology Collaborate to Support the Preclinical Study of Lixte’s Protein Phosphatase 2A Inhibitor, LB-100, as a Possible Treatment for Angelman SyndromeThe Foundation for Angelman Syndrome Therapeutics (FAST) and Lixte Biotechnology Collaborate to Support the Preclinical Study of Lixte’s Protein Phosphatase 2A Inhibitor, LB-100, as a Possible Treatment for Angelman Syndrome
finance.yahoo.com - December 23 at 10:48 AM
Lixte Biotechnology Holdings, Inc. Announces Pricing of $5,700,000 Public Offering; Uplisting to Nasdaq Capital Market and Reverse Stock SplitLixte Biotechnology Holdings, Inc. Announces Pricing of $5,700,000 Public Offering; Uplisting to Nasdaq Capital Market and Reverse Stock Split
finance.yahoo.com - December 23 at 10:48 AM
DateCompanyBrokerageAction
1/28/2021SoligenixB. RileyReiterated Rating
12/23/2020SoligenixAlliance Global PartnersLower Price Target
7/28/2020SoligenixDawson JamesDowngrade
6/25/2020SoligenixMaxim GroupInitiated Coverage
9/1/2020Regulus TherapeuticsHC WainwrightReiterated Rating
7/24/2020Regulus TherapeuticsWedbushReiterated Rating
5/15/2020Regulus TherapeuticsNeedham & Company LLCInitiated Coverage
3/19/2019Regulus TherapeuticsWells Fargo & CompanyLower Price Target
(Data available from 4/21/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.